KRAS and cancer: ELI-002 is composed of a lipid-conjugated immune-stimulatory oligonucleotide (Amph-CpG-7909) and a combination of lipid-conjugated peptide-based antigens (Amph-Peptides) designated by “NP” to target a broad spectrum of KRAS mutations expressed in various cancers.